Table of Content


COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 7
Charts 8
McKesson Corporation - Key Company Facts 9
McKesson Corporation - Company Description 10
McKesson Corporation - Top Executives 11
McKesson Corporation- Top Executives Biographies 12
McKesson Corporation- Head Office & Locations 14
Head Office - Country 14
Key Subsidiaries 15
Key Joint Ventures 16
McKesson Corporation - Products and Services 17
Products 17
Services 18
McKesson Corporation - Historic Events 20
McKesson Corporation – Company’s Management Discussion 22
McKesson Corporation – Company’s Mission and Vision 24
Mission 24
Vision 24
McKesson Corporation - Corporate Strategy 25
McKesson Corporation - Business Description 27
U.S. Pharmaceutical Segment 28
Prescription Technology Solutions (RxTS) Segment 29
Medical-Surgical Solutions Segment 29
International Segment 30
McKesson Corporation - ESG Spotlight 31
Environment 31
Social 32
Corporate Governance 32
McKesson Corporation - SWOT Analysis 33
Overview 33
Strengths 35
Weaknesses 39
Opportunities 42
Threats 45
McKesson Corporation – PESTLE Analysis 47
Overview 47
Political Factors 49
Economic Factors 51
Social Factors 53
Technological Factors 55
Legal Factors 57
Environmental Factors 59
McKesson Corporation - Financial Deep Dive 60
Share Price Trend - Oct-2023 to Oct-2024 (Average Share Closing Price) 60
Profit and Loss Statement 62
Summary of Profit and Loss Statement 62
Balance Sheet 64
Summary of Balance Sheet 64
Cash Flow Statement 66
Summary of Cash Flow Statement 66
Key Financial Ratio Analysis 68
McKesson Corporation - Ratio Charts 69
Activity Ratio Charts 69
Growth Ratios Charts 70
Leverage Ratio Charts 71
Liquidity Ratio Charts 72
Profitability Ratio Charts 73
Competing Players 74
Snapshot of Competing Players 75
Cencora Inc 75
Key Company Facts 75
Company Description 75
Snapshot of Competing Players 78
Cardinal Health Inc 78
Key Company Facts 78
Company Description 78
Snapshot of Competing Players 80
Johnson & Johnson Services, Inc. 80
Key Company Facts 80
Company Description 80
Snapshot of Competing Players 82
Medtronic plc 82
Key Company Facts 82
Company Description 82
Snapshot of Competing Players 84
Stryker Corporation 84
Key Company Facts 84
Company Description 84
McKesson Corporation - In the News 86
09-Oct-2024- InspiroGene by McKesson Unveils First-of-its-Kind Report on State of the Cell and Gene Therapy Landscape, Revealing Unparalleled Optimism Amidst Complex Challenges 86
01-Oct-2024- McKesson Launches InspiroGene, a Dedicated Business to Guide and Support the Commercialization of Cell and Gene Therapies 88
25-Sep-2024- VORANIGO (vorasidenib), FDA Approved for the Treatment of Patients with IDH-mutant Diffuse Glioma, Available at Biologics by McKesson 89
10-Sep-2024- ZOKINVY (lonafarnib), the only FDA Approved Treatment for Hutchinson-Gilford Progeria Syndrome, Now Exclusively Available at Biologics by McKesson 90
09-Sep-2024- RYTELOTM (imetelstat), FDA Approved for Treatment of Patients with Low- to Intermediate-1 Risk Myelodysplastic Syndromes (MDS) with Transfusion-dependent Anemia, Available at Biologics by McKesson 91
05-Sep-2024- McKesson Corporation Announces Sale of Rexall and Well.ca Businesses to Birch Hill Equity Partners 92
03-Sep-2024- The US Oncology Network Extends its Reach in Illinois as Illinois CancerCare Joins The Network 93
02-Jul-2024- McKesson Releases Fiscal Year 2024 Impact Report 95
26-Jun-2024- McKesson Corporation Announces First Quarter Fiscal 2025 Earnings Release Date 95
26-Jun-2024- McKesson ideaShare Ignites and Inspires Independent Community Pharmacies 95
19-Jun-2024- CAMCEVI (leuprolide) 42mg injection emulsion, FDA Approved for Treatment of Advanced Prostate Cancer, Available Exclusively at Biologics by McKesson 98
03-Jun-2024- McKesson’s Board of Directors Elects Deborah Dunsire as New Director 99
03-Jun-2024- Real-World Research Presented at ASCO 2024 Indicates Clinical Trial Participation by Older Adults with Cancer Does Not Affect Emergency Room Visits or Hospice Enrollment 100
20-Dec-2023- FABHALTA (iptacopan), FDA Approved for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria, Available at Biologics by McKesson 101
16-Aug-2023- Genpact Extends Relationship to Transform McKesson’s Finance Operations for Enhanced Service and Competitive Growth 101
10-Jul-2023- Cancer center of kansas joins the us oncology network 103
22-Jun-2023- Mckesson unveils new private brand of over-the-counter pharmacy products 104
05-Jun-2023- Research presented at asco 2023 shows implementing value-based care strategies such as dose rounding reduces drug waste and total cost of care 105
05-Apr-2023- Biologics by mckesson named the exclusive pharmacy for fda- approved skyclarys (omaveloxolone) for the treatment of friedreich’s ataxia 106
17-Jan-2023- The us oncology network continues its rapid growth into new communities, adding epic care and nexus health 107
22-Dec-2022- Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound), fda approved for treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor 109
McKesson Corporation- Key Deals 110
17-Oct-2024 - Ontada Collaborates with Microsoft to Transform Unstructured Oncology Data with Azure OpenAI Technology 110
26-Aug-2024 - McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute’s Core Ventures 112
19-Sep-2022 - Mckesson signs agreement to acquire rx savings solutions 114
09-May-2022 - Oncohealth secures strategic investments from arsenal capital partners & mckesson corporation 116
Appendix 118
Definitions 118
SWOT Analysis 118
PESTLE Analysis 118
Value Chain Analysis 118
ESG Spotlight 118
Financial Deep Dive 118
Financial Ratios - 119
Activity Ratios 119
Growth Ratios 120
Leverage Ratios 121
Liquidity Ratios 122
Market Ratios 123
Profitability Ratios 123
Research Methodology 124
Disclaimer 125
Contact Us 125



List of Figures

Charts
Figure 1: McKesson Corporation- SWOT Analysis 34
Figure 2: McKesson Corporation - PESTLE Analysis 48
Figure 3: McKesson Corporation - Average Share Price Trend - Oct-2023 to Oct-2024 61
Figure 4: McKesson Corporation - Profit and Loss Statement - 2021-2024 63
Figure 5: McKesson Corporation - Balance Sheet - 2021-2024 65
Figure 6: McKesson Corporation - Cash Flow Statement 2021-2024 67
Figure 7: McKesson Corporation - Activity Ratio Charts 69
Figure 8: McKesson Corporation - Growth Ratio Charts (Value %) 70
Figure 9: McKesson Corporation - Leverage Ratio Charts 71
Figure 10: McKesson Corporation - Liquidity Ratio Charts 72
Figure 11: McKesson Corporation - Profitability Ratio Charts (Value %) 73
Figure 12: Competing Players - Cencora Inc - Key Financials 77
Figure 13: Competing Players - Cardinal Health Inc - Key Financials 79
Figure 14: Competing Players - Johnson & Johnson Services, Inc. - Key Financials 81
Figure 15: Competing Players - Medtronic plc - Key Financials 83
Figure 16: Competing Players - Stryker Corporation - Key Financials 85

List of Tables

Tables
Table 1: McKesson Corporation - Company Facts 9
Table 2: McKesson Corporation - Top Executives 11
Table 3: McKesson Corporation - Top Executives Biographies 12
Table 4: McKesson Corporation - Subsidiaries 15
Table 5: McKesson Corporation - Key Joint Ventures 16
Table 6: McKesson Corporation - Products 17
Table 7: McKesson Corporation - Services 18
Table 8: McKesson Corporation - Historic Events 20
Table 9: McKesson Corporation - Share Price Trend - Oct-2023 to Oct-2024 60
Table 10: McKesson Corporation- Ratio Analysis - 2021-2024 68
Table 11: McKesson Corporation -Competing Players 74